Strategic Collaborations Intract Pharma has a history of partnering with big pharma and biotech players (Merck, Bio-Thera, Celltrion, Tharimmune) and is actively expanding through EU-funded programs with Bio-Sourcing. This indicates a receptive channel for co-development, licensing, and strategic alliances to accelerate commercialization of oral biologic platforms.

Oral Biologic Opportunity The core value proposition centers on converting injectable biologics into take-at-home oral pills for GI and systemic autoimmune diseases. This creates multi-therapeutic sales scenarios across monoclonal antibodies, offering potential licensing or co-development deals with mAb owners seeking oral delivery solutions.

Targeted Markets Focus on inflammatory diseases of the GI tract and systemic immune-mediated conditions aligns with high-value, chronic therapies. Opportunities exist to partner with developers of anti-TNF and other cytokine inhibitors, as well as pharmaceutical companies seeking GI-targeted drug delivery improvements.

Funding Signals EU-funded programs and multi-party collaborations signal accessible grant-supported development milestones. This can de-risk early-stage engagements and attract investors or customers interested in joint funding of pipeline advancement and platform validation.

Speed to Pilot Existing technology platforms Phloral and Soteria offer precision colon delivery and systemic immunomodulation, which can enable rapid scoping discussions for pilot programs, including feasibility studies with prospective biopharma partners aiming to convert existing biologics into oral formats.